相似文献
1
ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer.
Clin Pharmacol Ther. 2015 May;97(5):447-50. doi: 10.1002/cpt.91. Epub 2015 Apr 3.
2
ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.
Clin Cancer Res. 2015 Dec 15;21(24):5439-44. doi: 10.1158/1078-0432.CCR-15-0354.
3
Molecular oncology of lung cancer.
Gen Thorac Cardiovasc Surg. 2011 Aug;59(8):527-37. doi: 10.1007/s11748-010-0743-3. Epub 2011 Aug 18.
4
Personalized targeted therapy for lung cancer.
Int J Mol Sci. 2012;13(9):11471-11496. doi: 10.3390/ijms130911471. Epub 2012 Sep 13.
5
Present and future molecular testing of lung carcinoma.
Adv Anat Pathol. 2014 Mar;21(2):94-9. doi: 10.1097/PAP.0000000000000012.
6
EGFR and EML4-ALK Updated Therapies in Non-Small Cell Lung Cancer.
Recent Pat Anticancer Drug Discov. 2016;11(4):393-400. doi: 10.2174/1574892811666160803090944.
7
Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer.
Drug Des Devel Ther. 2015 Oct 3;9:5491-7. doi: 10.2147/DDDT.S91988. eCollection 2015.
8
Improving Selection Criteria for ALK Inhibitor Therapy in Non-Small Cell Lung Cancer: A Pooled-Data Analysis on Diagnostic Operating Characteristics of Immunohistochemistry.
Am J Surg Pathol. 2016 May;40(5):697-703. doi: 10.1097/PAS.0000000000000604.
9
Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.
Lung Cancer. 2015 Oct;90(1):1-7. doi: 10.1016/j.lungcan.2015.07.016. Epub 2015 Jul 30.
10
Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
BMC Cancer. 2020 Apr 16;20(1):328. doi: 10.1186/s12885-020-06805-5.
引用本文的文献
1
Emerging Role of Molecular Testing in the Management of Non-metastatic Non-small Cell Lung Cancer.
Tuberc Respir Dis (Seoul). 2025 Jul;88(3):431-441. doi: 10.4046/trd.2024.0159. Epub 2025 Mar 26.
2
Design and analysis of umbrella trials: Where do we stand?
Front Med (Lausanne). 2022 Oct 12;9:1037439. doi: 10.3389/fmed.2022.1037439. eCollection 2022.
3
Novel Inflammasome-Based Risk Score for Predicting Survival and Efficacy to Immunotherapy in Early-Stage Non-Small Cell Lung Cancer.
Biomedicines. 2022 Jun 28;10(7):1539. doi: 10.3390/biomedicines10071539.
4
Effect of almonertinib on the proliferation, invasion, and migration in non-small cell lung cancer cells.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2021 Oct 28;46(10):1045-1053. doi: 10.11817/j.issn.1672-7347.2021.201009.
5
Innovative trial approaches in immune-mediated inflammatory diseases: current use and future potential.
BMC Rheumatol. 2021 Jul 2;5(1):21. doi: 10.1186/s41927-021-00192-5.
6
Treatment allocation strategies for umbrella trials in the presence of multiple biomarkers: A comparison of methods.
Pharm Stat. 2021 Nov;20(6):990-1001. doi: 10.1002/pst.2119. Epub 2021 Mar 24.
7
Transcriptomics and solid tumors: The next frontier in precision cancer medicine.
Semin Cancer Biol. 2022 Sep;84:50-59. doi: 10.1016/j.semcancer.2020.09.007. Epub 2020 Sep 17.
8
Early-Phase Platform Trials: A New Paradigm for Dose Finding and Treatment Screening in the Era of Precision Oncology.
JCO Precis Oncol. 2019 Oct 24;3. doi: 10.1200/PO.19.00057. eCollection 2019.
9
Review of precision cancer medicine: Evolution of the treatment paradigm.
Cancer Treat Rev. 2020 Jun;86:102019. doi: 10.1016/j.ctrv.2020.102019. Epub 2020 Mar 31.
10
Precision medicine and actionable alterations in lung cancer: A single institution experience.
PLoS One. 2020 Feb 11;15(2):e0228188. doi: 10.1371/journal.pone.0228188. eCollection 2020.
本文引用的文献
1
Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project.
J Clin Oncol. 2014 Sep 1;32(25):2780-7. doi: 10.1200/JCO.2013.54.5921. Epub 2014 Jul 28.
2
Management and future directions in non-small cell lung cancer with known activating mutations.
Am Soc Clin Oncol Educ Book. 2014:e353-65. doi: 10.14694/EdBook_AM.2014.34.e353.
3
Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma.
J Thorac Oncol. 2012 Jan;7(1):90-7. doi: 10.1097/JTO.0b013e31823c5c32.
4
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.
Sci Transl Med. 2011 Mar 23;3(75):75ra26. doi: 10.1126/scitranslmed.3002003.
5
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
J Clin Oncol. 2008 Jul 20;26(21):3552-9. doi: 10.1200/JCO.2007.13.9030. Epub 2008 May 27.
Zotero 插件